4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $502,800 | -3.4% | 39,481 | +37.0% | 0.00% | 0.0% |
| Q2 2023 | $520,334 | +5.0% | 28,814 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $495,656 | -48.5% | 28,814 | -31.7% | 0.00% | 0.0% |
| Q4 2022 | $961,569 | +105.5% | 42,185 | -27.6% | 0.00% | 0.0% |
| Q3 2022 | $468,000 | +31.5% | 58,256 | +14.0% | 0.00% | 0.0% |
| Q2 2022 | $356,000 | -12.3% | 51,108 | +90.2% | 0.00% | 0.0% |
| Q1 2022 | $406,000 | +50.4% | 26,872 | +118.1% | 0.00% | +100.0% |
| Q4 2021 | $270,000 | -14.0% | 12,320 | +5.8% | 0.00% | 0.0% |
| Q3 2021 | $314,000 | +24.1% | 11,648 | +11.0% | 0.00% | 0.0% |
| Q2 2021 | $253,000 | -44.4% | 10,495 | 0.0% | 0.00% | -50.0% |
| Q1 2021 | $455,000 | +4.6% | 10,495 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $435,000 | – | 10,495 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |